1 / 28

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis. Learning Goals. Case 1: Introduction (JS). Validated Quantitative Measures of Disease Activity. Features of Disease Activity Measurement Tools. Features of Disease Activity Measurement Tools (cont).

fancy
Download Presentation

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis

  2. Learning Goals

  3. Case 1: Introduction (JS)

  4. Validated Quantitative Measuresof Disease Activity

  5. Features of Disease Activity Measurement Tools

  6. Features of Disease Activity Measurement Tools (cont)

  7. Assessing Disease Activity in RA

  8. Key Principles

  9. ACR Recommendations forTreating Early RA

  10. Poor Prognostic Features

  11. ACR / EULAR Definitions of Remission

  12. A Tablet-based Application to Facilitate Assessment of RA Disease Activity

  13. The READY Application

  14. Usual Workflow to Collect RADisease Activity Data

  15. Features of the READY iPadApplication

  16. Case 2: Introduction (RM)

  17. Case 2 (cont)

  18. RA Therapies

  19. Switching From DMARDS to Biologics

  20. Switching Among Biologics Due to Lack of Response or Loss of Benefit

  21. Switching Among Biologics Due toAdverse Events

  22. Switching Among Biologics Due toAdverse Events (cont)

  23. Switching Among Biologics Due toAdverse Events (cont)

  24. Abbreviations

  25. Abbreviations (cont)

  26. References

More Related